Background: Data on the prevalence of perennial versus seasonal allergic asthma in Italy are lacking; moreover, there is limited evidence on the effect of omalizumab on patient-reported outcomes in Italian patients with severe allergic asthma. PROXIMA, an observational, multicenter study, was designed to assess the prevalence of perennial versus seasonal allergic asthma (cross-sectional phase) and the effect of omalizumab on improving illness perception, quality of life (QoL) and asthma control of Italian patients with severe allergic asthma (longitudinal phase). Methods: The study included a cross-sectional phase (n = 357) and a longitudinal phase (n = 123): during the longitudinal phase, patients received omalizumab (75-600 mg subcutaneously every month) and were followed-up for 12 months. The primary parameter of cross-sectional phase was prevalence of perennial allergic asthma and that of longitudinal phase was proportion of patients with asthma control (assessed using asthma control questionnaire [ACQ]). Secondary parameters assessed were patients' disease perception, level of asthma control, exacerbation rate during both cross-sectional and longitudinal phases, and patients' compliance to and persistence with omalizumab, and patients' QoL during the longitudinal phase. Results: Most patients (95.8%) had perennial allergies; 81% had polysensitization. Of 99 patients in the per-protocol set, 95 (95.96% [95% CI: 89.98-98.89%]) achieved asthma control (ACQ < 4) at both 6 and 12 months of omalizumab treatment; ACQ score decreased after 6 and 12 months (P < 0.0001). Omalizumab treatment resulted in a significant improvement in QoL and patients' illness perception and 87% decrease in exacerbation rate. The compliance rate with omalizumab was high (73.2%). No new safety signals were identified during treatment. Conclusion: This study demonstrated that in severe allergic asthma, omalizumab improves patient-reported outcomes such as patients' illness perception and QoL, while confirming improvement of asthma control and exacerbation rate reduction in Italian patients.
Improvement of patient-reported outcomes in severe allergic asthma by omalizumab treatment : the real life observational PROXIMA study / G.W. Canonica, P. Rottoli, C. Bucca, M.C. Zappa, G. Michetti, B. Macciocchi, C. Caruso, P. Santus, M. Bartezaghi, L. Rigoni. - In: THE WORLD ALLERGY ORGANIZATION JOURNAL. - ISSN 1939-4551. - 11:1(2018 Nov), pp. 33.1-33.11.
|Titolo:||Improvement of patient-reported outcomes in severe allergic asthma by omalizumab treatment : the real life observational PROXIMA study|
|Parole Chiave:||Asthma control; Exacerbations; Illness perception; Omalizumab; Perennial allergens; Quality of life; Seasonal allergens; Severe allergic asthma; Immunology and Allergy; Immunology; Pulmonary and Respiratory Medicine|
|Settore Scientifico Disciplinare:||Settore MED/10 - Malattie dell'Apparato Respiratorio|
Settore MED/09 - Medicina Interna
|Data di pubblicazione:||nov-2018|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1186/s40413-018-0214-3|
|Appare nelle tipologie:||01 - Articolo su periodico|